TrialJournal for immunotherapy of cancer2024

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).

Michael B Atkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.